

30th October, 2024

To,
The BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Dear Sir

Sub : Outcome of the Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

BSE Code : 531210

We would like to inform you that, the Board of Directors of the Company at their meeting held today i.e. **30th October, 2024** has, inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on **30th September, 2024**.

Enclosed herewith a copy of the same along with a copy of Limited Review Report dated **30th October, 2024** received from Vora & Associates, Chartered Accountants, Statutory Auditors of the Company with respect to Unaudited Financial Results for the quarter and half year ended on **30th September, 2024**.

The Meeting commenced at 3:30 P.M. and concluded at 5.00 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

FOR COLINZ LABORATORIES LTD

DR. MANI L. S.
Chairman of the Meeting



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123



Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To
The Board of Directors,
COLINZ LABORATORIES LIMITED.

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **COLINZ LABORATORIES LIMITED** ('the Company') for the half year ended 30th September, 2024 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34') prescribed u/s 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CF/FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)


RONAK A. RAMBHIA
PARTNER

(Membership No.: 140371)

UDIN: 24140371BKALJR7196
PLACE: MUMBAI
DATED: October 30, 2024

COLINZ LABORATORIES LIMITED.


(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED " 30th SEPTEMBER, 2024"

"(Rs. In Lakhs)"

S. No.	Particulars	Un-Audited					Audited
		Quarter ended			Six Month Ended		Year Ewinded
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
PART - I							
1	(a) Revenue from Operation	186.31	174.66	178.62	360.97	368.56	702.96
3	(b) Other Income	7.77	6.73	7.59	14.50	12.02	27.50
3	Total Income from Operation	194.08	181.39	186.21	375.47	380.58	730.46
4	Expenses						
	(a) Cost Of Material Consumed	14.14	15.29	15.72	29.43	32.96	50.87
	(b) Purchase of Stock in Trade	42.36	34.98	49.48	77.34	86.11	172.35
	(c) Change in Inventories Of Finished Goods and Work in Progress and Stock in Trade	(0.92)	5.61	(7.72)	4.69	(1.61)	8.11
	(d) Employee Benefit Expenses	73.42	72.10	80.09	145.52	159.05	295.05
	(e) Finance Cost	1.16	0.93	0.92	2.09	1.73	3.72
	(f) Depreciation & Amortisation Expenses	3.22	3.22	3.26	6.44	6.52	13.03
	(g) Other Expenses	39.88	30.79	28.39	70.67	64.38	122.30
	Total Expenses	173.26	162.92	170.14	336.18	349.14	665.43
5	Profit / (Loss) Before exceptional items and tax (3-4)	20.82	18.47	16.07	39.29	31.44	65.03
6	Exceptional items	-	-	-	-	-	-
7	Profit / (Loss) before tax (5-6)	20.82	18.47	16.07	39.29	31.44	65.03
8	Tax Expenses (Provision for Taxation) Current tax						
	i) Current Tax	5.25	4.75	3.75	10.00	7.00	17.75
	ii) Deffered Tax	-	-	-	-	-	(0.15)
	iii) Tax for earlier years	-	-	-	-	-	(1.24)
	iv) MAT Credit of Earlier years	-	-	-	-	-	-
9	Profit / (Loss) for the period from continuing operations(7-8)	15.57	13.72	12.32	29.29	24.44	48.67
10	Profit / (Loss) for the period	15.57	13.72	12.32	29.29	24.44	48.67
11	Other Comprehensive Income (Net of Tax)						
	A) Item that will not be reclassified to Profit or Loss Account						
	i) Change in fair value of investment in Equity Instruments	2.28	8.20	3.42	10.48	14.82	32.30
12	Total Comprehensive Income for the period (10+11) Comprising	17.85	21.92	15.74	39.77	39.26	80.97
13	Earning per equity share (for Continuing operation) (In Rs.)						
	i) Basic	0.62	0.54	0.49	1.16	0.97	1.93
	ii) Diluted	0.62	0.54	0.49	1.16	0.97	1.93



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123

STATEMENT OF ASSETS AND LIABILITIES

Particulars	30-Sep-24	31-Mar-2024
Non-Current Assets		
a) Property, Plants & Equipment	151.44	157.89
b) Capital Work-in progress	-	-
c) Intangible Assets	-	-
d) Financial Assets		
i) Investments	113.81	102.18
ii) Loans	-	-
iii) Other Financial Assets	-	-
e) Other Non Current Assets	4	2.35
Total Non-Current Assets	269.25	262.42
Current Assets		
a) Inventories	77.66	84.69
b) Financial Assets		
i) Trade Receivables	82.49	85.92
ii) Cash & Cash Equivalents	386.28	294.66
iii) Other Bank Balances	417.79	405.35
iv) Other Financial Assets	-	-
c) Other Current Assets	2.49	2.90
Total Current Assets	966.71	873.52
TOTAL ASSETS	1235.96	1135.94
EQUITY AND LIABILITIES		
Equity		
a) Equity Share Capital	251.91	251.91
b) Other Equity	682.74	642.98
Total Equity	934.65	894.89
Liabilities		
Non-Current Liabilities		
a) Deferred Tax Liabilities (Net)	24.06	22.90
b) Other Non Current Liabilities	-	-
Total Non-Current Liabilities	24.06	22.90
Current Liabilities		
a) Financial Liabilities		
i) Borrowings	81.08	56.98
ii) Trade Payables	69.20	59.76
b) Other Current Liabilities	117.9	92.34
c) Current Provisions	9.07	9.07
Total Current Liabilities	277.25	218.15
TOTAL EQUITY AND LIABILITIES	1235.96	1135.94


Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123





COLINZ LABORATORIES LTD.

CASH FLOW STATEMENT FOR THE YEAR ENDED 30-09-2024

(Rs. In Lacs)

	April 01, 2024 To Sept. 30, 2024	April 01, 2023 To Sept. 30, 2023
A) CASH FLOW FROM OPERATING ACTIVITIES:		
Profit Before Taxation	39.29	31.44
Adjustments for:		
Depreciation/Impairment	6.45	6.52
Loss on sale of Assets	0.00	0.00
Interest Expense	2.08	1.73
Interest Income	(13.82)	(11.43)
Dividend Income	(0.68)	(0.60)
Operating Profit Before Working Capital Changes	33.32	27.66
Adjustments for changes in working capital:		
Increase / (Decrease) in Trade Payable	9.44	(3.39)
Increase / (Decrease) in Short Term Borrowings	24.10	18.69
Increase / (Decrease) in Current Provisions	0.00	0.00
Increase / (Decrease) in Other Current Liabilities	25.56	21.58
Increase / (Decrease) in Other Long Term Current Liabilities	0.00	0.00
(Increase) / Decrease in Trade Receivables	3.43	(6.85)
(Increase) / Decrease in Inventories	7.03	2.40
(Increase) / Decrease in Other Non Current Assets	0.00	0.00
(Increase) / Decrease in Other Current Assets	0.41	0.57
Cash Generated /(Used In) from Operations	103.29	60.66
Taxes Paid (Net)	(11.65)	(9.11)
Net Cash generated from /(Used In) Operating Activities	91.64	51.55
B) CASH FLOW FROM INVESTING ACTIVITIES:		
Purchase/Sales of Fixed Assets	0.00	0.00
Investments in shares & securities (Net)	0.00	0.00
Call Money Received(Shares)	0.00	0.00
Dividend Income	0.68	0.60
Net Cash (Used In) Investing Activities	0.68	0.60
C) CASH FLOW FROM FINANCING ACTIVITIES:		
Interest received	13.82	11.43
Interest Expense	(2.08)	(1.73)
Net Cash (Used In) /generated from Financing Activities	11.74	9.69
Net increase in Cash and Cash Equivalents (A+B+C)	104.06	61.84
Cash and Cash Equivalents as at the beginning of the year	700.01	572.89
Cash and Cash Equivalents as at the end of the year	804.07	634.73
	104.06	61.84
Cash and Cash Equivalents comprise of:		
Cash in Hand	1.12	1.62
Balances with Scheduled Banks in:		
- Current Accounts	385.16	246.49
Other Bank Balances	417.79	386.62
	804.07	634.73




NOTES TO THE FINANCIAL RESULTS :-



- 1) The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 30th Oct, 2024.
- 2) The above results of the Company has been audited by the Statutory Auditors and they have issued an unqualified audit opinion on the same.
- 3) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 4) Previous period figures have been regrouped/ rearranged / reclassified, wherever necessary.
- 5) In accordance with regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulation, 2015, The Audited Results for Quarter and period ended **30th September, 2024** are available on the BSE website (URL: www.bselindia.com) and the Company's website (URL: www.findoc-cll.in).

Place : Mumbai
Date : 30-10-2024

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128



Dr. MANI L. S.
(Chairman of the Meeting & Authorised Director)
(DIN NO : 00825886)



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123